Follow us for updates
© 2022
Read the Story →

How to Spot Fake Bioflu, Diatabs, According to the FDA

Counterfeit drugs have been spotted in the market.
by Pia Regalado
Sep 14, 2021
Photo/s: Pixabay / Pexels

The Food and Drug Administration on Tuesday warned the public againt buying and using conterfeit versions of five drugs in the market, as it gave tips on how to spot fakes.

The regulator said fake versions of these drugs are circulating in the market:

1. Dexamethasone (Decilone Forte) 4 mg tablet with lot no. A022312
2. Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Bioflu) 10 mg / 2 mg / 500 mg tablet with lot no. U099126
3. Loperamide (Diatabs) 2 mg capsule with lot no. U650892
4. Loperamide HCl (Lomotil) 2 mg tablet with lot no. 15LMT05
5. Loperamide (Imodium) 2 mg capsule with lot no. 65C-21

The FDA said counterfeit products could harm consumers. It reminded the public to buy medicines from FDA-licensed establishments to ensure quality.

To check if the product is registered with the FDA, visit its verification portal here:

Here's how to spot if the product is fake:

Decilone Forte

Continue reading below ↓


Continue reading below ↓
Recommended Videos




Continue reading below ↓



Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
President cites 'substantial fiscal risks'.
With the reopening of several local destinations, this app has never been more timely.
A busy end of 2022 for the concert scene.
The Marcos children made sure his memory was there.
It comes with great responsibility.
It wants to become a 'super-app' for messaging instead. Here's how.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.